# Entrada Therapeutics, Inc. (TRDA): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Entrada Therapeutics, Inc. (TRDA) is 7/100, ranked against 24,000+ stocks in 35 markets (Quality 20, Value 34, Momentum 24, each scored against its sector).

- StockRank: 7/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 20, Value 34, Momentum 24: each a 0-100 percentile within Healthcare.
- Position: #24,484 overall, #2,391 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 4.75 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 29K; directors sold USD 2.5M; 5%+ holders sold USD 4.8M.

Source: https://moatmap.ai/stock/TRDA
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker